Wyeth case could affect provider liability

January 2009
Healthcare Risk Management;Jan2009, Vol. 31 Issue 1, p5
The article focuses on the ruling from the U.S. Supreme Court involving a case of Wyeth that is said to have an impact on drug labeling and the liabilities of manufacturers for not following labeling guidelines correctly.


Related Articles

  • Background: Wyeth case centers on labeling.  // Healthcare Risk Management;Jan2009, Vol. 31 Issue 1, p6 

    The article presents the background of a case involving the pharmaceutical company Wyeth regarding drug labeling.

  • Prempro: The New Fen-Phen for Wyeth's Lawyers. Reisinger, Sue // Corporate Legal Times;Jan2003, Vol. 13 Issue 134, p48 

    Reports on the lawsuits filed against New Jersey drugmaker Wyeth Inc. Background of the case; Allegations against Wyeth's Prempo drug to cause side effects; Actions taken by the court.

  • Rebuttal to Attack Against Bioidentical Hormones. Faloon, William // Life Extension;Jun2008, Vol. 14 Issue 6, p7 

    The article offers health- and medical-related topics. A flawed study published in a medical journal questioned the value of natural testosterone replacement. Results of a study that analyzed the relationship of natural hormones, such as free testosterone, to death rates in men suffering from...

  • Vaccine Preemption Upheld.  // BioWorld Today;2/25/2011, Vol. 22 Issue 38, p4 

    The article reports on the ruling of the U.S. Supreme Court in Bruesewitz v. Wyeth LLC in which they upheld the National Childhood Vaccine Injury Act of 1986 that dismisses the liability for unavoidable adverse side effects of a vaccine, which is manufactured and labeled based on its U.S. Food...

  • Two Masters. Schneider, Carl E. // Hastings Center Report;Jan2010, Vol. 40 Issue 1, p9 

    The article discusses a court case wherein the pharmaceutical firm Wyeth was found negligent for a defective product called Phenergan and was asked to pay 7.4 million U.S. dollars to the plaintiff. In Wyeth v. Levine, the latter alleged that Phenergan was not reasonably safe for intravenous...

  • So Far, Victories Are Few as Breast Cancer Patients Sue Wyeth Over Hormone Therapy. Twombly, Renee // JNCI: Journal of the National Cancer Institute;12/19/2007, Vol. 99 Issue 24, p1828 

    The article reports on the lawsuit filed against Wyeth regarding its hormone replacement drugs which are said to be causes of cancer among women. It is mentioned that the pharmaceutical company is listed as defendant on 5,300 cases filed by 7,900 plaintiffs for its manufactured estrogen...

  • High Court showdown for Wyeth, woman who lost forearm. Greenwald, Judy // Business Insurance;6/30/2008, Vol. 42 Issue 26, p28 

    The article focuses on the case Wyeth vs. Diana Levine. The major focus on this case is whether federal regulations pre-empt the lawsuit against the drug manufacturer. The U.S. Supreme Court's ruling in the drug labeling case also could affect federal pre-emption of state product liability...

  • Wyeth Faces New Damages Trial. WILLIAMSON, LAUREN // InsideCounsel;Jan2010, Vol. 21 Issue 217, p60 

    The article reports on the ruling of the U.S. Court of Appeals for the Eighth Circuit on November 2, 2009 in a case involving Wyeth and Upjohn.

  • Vaccine Defect Claims Pre-empted. WILLIAMSON, LAUREN // InsideCounsel;Jun2009, Vol. 20 Issue 210, p77 

    The article discusses the court case Bruesewitz v. Wyeth Inc., wherein the 3rd Circuit affirmed the granting of summary judgment in favor of the defendant by a lower court. It was argued that all design defect claims are pre-empted by the National Childhood Vaccine Injury Act. Vaccine...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics